A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With GEP-NET (SORENTO)


Some of the key differences between Lanreotide and Octreotide long-acting are:

1.  Octreotide long-acting needs constituting prior to administration – Lanreotide comes prefilled. 

2. Octreotide long-acting is administered intra-muscular, Lanreotide is deep subcutaneous. 

3.  I probably should add Octreotide LAR cannot be self-injected but Lanreotide can.  I suspect this type of delivery system may open up that possibility for Octreotide LAR. 

So, this clinical trial caught my eye.  A version of octreotide long-acting which is prefilled and given subcutaneously.  Plus, the manufacturers say it has a much higher bioavailability than the standard product Sandostatin LAR (bioavailability is the proportion of a drug or other substance which enters the circulation when introduced into the body and so is able to have an active effect).

CAM2029 might therefore be considered a generic of Sandostatin LAR but better both in the delivery system and bioavailability. 

What is CAM2029?

CAM2029 is developed for the treatment of acromegaly and neuroendocrine tumors. The product candidate offers important potential advantages over currently marketed products, including easy administration, significantly increased bioavailability, and potential for enhanced treatment efficacy in patients for whom current treatments provide suboptimal treatment effects.

CAM2029 is a ready-to-use, long-acting subcutaneous injection depot based on the active substance octreotide formulated with Camurus’ proprietary FluidCrystal® injection depot technology. It is provided as a prefilled syringe, thus not requiring any reconstitution or conditioning prior to administration. Due to the superior ease of handling and administration, CAM2029 can be conveniently administered by the patients themselves.

CAM2029 – Key target attributes
• Subcutaneous long-acting octreotide
• Fast onset and one month duration of therapeutic plasma-levels
• Provided ready-for-use in prefilled syringes for easy self-administration
• Compatible with autoinjectors
• High bioavailability – 500% higher than Sandostatin® LAR®, with potential for better treatment effects in some patients

CAM2029 – Key publications
1. Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study
Pavel M, Borson‑Chazot F, Cailleux A, Hörsch D, Lahner H, Pivonello R, Tauchmanova L, Darstein C, Olsson H, Tiberg F, Ferone D., Cancer Chemotherapy and Pharmacology (2019) 83:375–385

2. Camurus announces dosing initiated in Phase 3 study of CAM2029 in patients with Neuroendocrine Tumors. 

The Sorento Clinical Trial

Purpose: The purpose of this study is to compare the effectiveness and safety of CAM2029 to both Octreotide LAR (Sandostatin LAR) or Lanreotide Autogel in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.

Who can take part?  Make sure you read all of the inclusion and exclusion details in the clinical trial.  I picked out a key one for each.  Included – Histologically confirmed, advanced (unresectable and/or metastatic), and well-differentiated NET of GEP or presumed GEP origin. Excluded – Previously received radioligand therapy (PRRT) at any time.

Where are the trials taking place? United States (Texas), Italy, Spain (4 hospitals). The principal investigator is well-known Canadian NET specialist Simron Singh MD.  They are looking for 300 participants across all sites. Recruiting now according to the clinical trials document. 

The full clinical trial document can be found here

Great video of FluidCrystal® injection depot from the manufacturer but it’s not clear whether any authorised drug delivery system would look like this, it could be a prototype and/or just for clinical trial use. 

General Clinical Trials Disclaimer

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact. 

Inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan. 


Subscribe to my newsletter

Thanks for reading.


I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’

Sign up for my newsletters – Click Here


My Diagnosis and Treatment History

Follow me on twitter

Check out my online presentations

Check out my WEGO Health Awards

Like my new awareness page – click here or on the photo.  (Like rather than follow please!)

Remember ….. in the war on Neuroendocrine Cancer, let’s not forget to win the battle for better quality of life!

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient


Neuroendocrine Cancer: Glossary of Terms

Welcome to my Neuroendocrine Cancer terms and definitions list providing a source of meanings for acronyms and medical terms, all sourced from top Neuroendocrine Cancer and

Read More »

Opinion: On Rare Cancer Day, what’s wrong with a bit of Neuroendocrine Cancer awareness?

On Rare Cancer Day, what’s wrong with a bit of Neuroendocrine Cancer awareness?  Well, there are three main things wrong with Neuroendocrine Cancer awareness: 1.

Read More »

Prospective Phase II Trial of Prognostication by 68Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy

Summary A novel PET radiotracer can accurately assess the presence of a biomarker that indicates the level of tumor aggressiveness in neuroendocrine neoplasms (NENs). According

Read More »

Living with cancer: 5 tips for facing things you can’t control

I’m wired not to worry too much about something I cannot control.  For example, I automatically ignore any concerns about being inside an imaging device

Read More »

A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (MAST)

A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (MAST) Neuroendocrine

Read More »

Neuroendocrine Cancer: When you get years added to your life, it’s important to get life added to your years

Self Pity or Self Help?  I’m not one for wallowing in self-pity or accepting invites to pity parties.  It’s not my style. Things happen in

Read More »

Opinion: Neuroendocrine Cancer – remission, cancer-free, no evidence of disease

An opinion post Cure I once wrote an article called “Neuroendocrine Cancer – can it be cured“.  In that article, I covered the fact that

Read More »

Clinical Trial: Phase 1b/3 Targeted Alpha-Emitter PRRT RYZ101 (Ac225)

What is RYZ101? RYZ101 is an investigational targeted alpha-emitter radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing SSTR2. RYZ101

Read More »

Lung nodules – something or nothing?

Background A focus on the issue of Lung nodules given I see these mentioned all the time in my online patient group, on many occasions

Read More »

6 thoughts on “A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With GEP-NET (SORENTO)

I love comments - feel free!

%d bloggers like this: